Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome

References

• Hull M GR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987; 1: 235–245
   PubMedGoogle Scholar
• Polson D W, Adams J, Wadsworth J, Franks S. Polycystic ovaries – a common finding in normal women. Lancet 1988; 1: 870–872
   PubMed Web of Science ®Google Scholar
• Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli C R, Bergiele A T, Filandra F A, Tsianateli T C, Spina G G, Zapanti E D, Bartzis M I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006–4011
   PubMed Web of Science ®Google Scholar
• Norman R J. Hyperandrogenaemia and the ovary. Mol Cell Endocrinol 2002; 191: 113–119
   PubMedGoogle Scholar
• Lobo R A, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989–993
   PubMed Web of Science ®Google Scholar
• Ibanez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos M V, De Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 5702–5705
   PubMed Web of Science ®Google Scholar
• Ibanez L, de Zegher F, Potau N. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 1998; 21: 558–566
   PubMedGoogle Scholar
• Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004; 144: 23–29
   PubMed Web of Science ®Google Scholar
• Battaglia C, Regnani G, Mancini F, Iughetti L, Bernasconi S, Volpe A, Flamigni C, Venturoli S. Isolated premature pubarche: ultrasonographic and color Doppler analysis – a longitudinal study. J Clin Endocrinol Metab 2002; 87: 3148–3154
   PubMedGoogle Scholar
• Ong K K, Potau N, Petry C J, Jones R, Ness A R, Honour J W, de Zegher F, Ibanez L, Dunger D B. Avon Longitudinal Study of Parents and Children Study Team. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004; 89: 2647–2651
   PubMedGoogle Scholar
• Ibanez L, Potau N, Dunger D, de Zegher F. Precocious pubarche in girls and the development of androgen excess. J Pediatr Endocrinol Metab 2000; 13(Suppl 5)1261–1263
   PubMedGoogle Scholar
• Ibanez L, Valls C, Marcos M V, Ong K, Dunger D B, De Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 2004; 89: 4331–4337
   PubMedGoogle Scholar
• Abassi F, Reaver G M. Evaluation of the quantitative insulin sensitivity index as an estimate of insulin sensitivity in humans. Metabolism 2002; 51: 235–237
   PubMedGoogle Scholar
• Pierpoint T, McKeigue P M, Isaacs A J, Wild S H, Jacobs H S. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581–586
   PubMed Web of Science ®Google Scholar
• Norman R J, Masters L, Milner C R, Wang J X, Davies M J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001; 16: 1995–1998
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–1174
   PubMed Web of Science ®Google Scholar
• Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endocrinol 1994; 12: 15–20
   Google Scholar
• Burghen G A, Givens J R, Kitabchi A E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary disease. J Clin Endocrinol Metab 1980; 50: 113–116
   PubMed Web of Science ®Google Scholar
• Barbieri R L, Hornstein M D. Hyperinsulinemia and ovarian hyperandrogenism: cause and effect. Endocrinol Metab Clin North Am 1988; 17: 685–703
   PubMedGoogle Scholar
• Moghetti P, Tosi F, Castello R, Magnani C M, Negri C, Brun E, Furlani L, Caputo M, Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996; 81: 952–960
   PubMed Web of Science ®Google Scholar
• Legro R, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694–2698
   PubMed Web of Science ®Google Scholar
• Robinson S, Henderson A D, Gelding S V, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston D G, Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996; 44: 277–284
   PubMed Web of Science ®Google Scholar
• Birdsall M A, Farquhar C M. Polycystic ovaries in pre- and post-menopausal women. Clin Endocrinol (Oxf) 1996; 44: 269–276
   PubMedGoogle Scholar
• Meirow D, Raz I, Yossepowitch O, Brzezinski A, Rosler A, Schenker J G, Berry E M. Dyslipidaemia in polycystic ovary syndrome: different groups, different aetiologies?. Hum Reprod 1996; 11: 1848–1853
   PubMed Web of Science ®Google Scholar
• Wild R A. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995; 98(Suppl)27S–32S
   Google Scholar
• Birdsall M A, Farquhar C M, White H D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catherization. Ann Intern Med 1997; 126: 32–35
   PubMed Web of Science ®Google Scholar
• Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS. Reprod Biomed Online 2004; 9: 614–619
   PubMedGoogle Scholar
• Balen A H, Laven J S, Tan S L, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9: 505–514
   PubMed Web of Science ®Google Scholar
• Jarvela I Y, Sladkevicius P, Kelly S, Ojha K, Campbell S, Nargund G. Comparison of follicular vascularization in normal versus polycystic ovaries during in vitro fertilization as measured using 3-dimensional power Doppler ultrasonography. Fertil Steril 2004; 82: 1358–1363
   PubMedGoogle Scholar
• Stein I F, Leventhal M L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181–191
   Google Scholar
• Kistner R W. Peritubal and periovarian adhesions subsequent to wedge resection of the ovaries. Fertil Steril 1969; 20: 35–42
   PubMedGoogle Scholar
• Gjoannaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984; 4: 20–25
   Google Scholar
• Tulandi T. Atlas of laparoscopic and hysteroscopic techniques for gynecologists. Saunders, London, WB 1999; 93–95
   Google Scholar
• Daniel J F, Miller W. Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril 1989; 51: 232–236
   PubMedGoogle Scholar
• Felemban A, Tan S L, Tulandi T. Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertil Steril 2000; 73: 266–269
   PubMed Web of Science ®Google Scholar
• Li T C, Saravelos H, Chow M S, Chisabingo R, Cooke I D. Factors affecting the outcome of laparoscopic ovarian drilling for polycystic ovarian syndrome in women with anovulatory infertility. Br J Obstet Gynaecol 1998; 105: 338–344
   PubMedGoogle Scholar
• Heylen S M, Puttemans P J, Brosens I A. Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. Hum Reprod 1994; 9: 1038–1042
   PubMed Web of Science ®Google Scholar
• Greenblatt E, Camper R F. Endocrine changes after laparoscopic ovarian cutery in polycystic ovarian syndrome. Am J Obstet Gynecol 1987; 42: 517–518
   Google Scholar
• Kovacs G, Buckler H, Bangah M, Outch K, Burger H, Healy D, Baker G, Phillips S. Treatment of anovulation due to polycystic ovarian syndrome by laparoscopic ovarian cautery. Br J Obstet Gynaecol 1991; 98: 30–35
   PubMedGoogle Scholar
• Sumioki H, Utsunomiya T. Ovarian drilling. Fertility and reproduction medicine, L R Kempers, J Cohen, A F Haney, J B Yongers. Elsevier Science, New York 1998; 537–539
   Google Scholar
• Saleh A M, Khalil H S. Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2004; 83: 614–621
   PubMed Web of Science ®Google Scholar
• El Helw B A, Ghorab M NM, El Attar E. Surgical induction of ovulation in women with polycystic ovary syndrome: a critical analysis of published data. Middle East Fertility Society Journal 1996; 1
   Google Scholar
• Mio Y, Toda T, Tanikawa M, Terado H, Harada T, Terakawa N. Transvaginal ultrasound-guided follicular aspiration in the management of anovulatory infertility associated with polycystic ovaries. Fertil Steril 1991; 56: 1268–1269
   Google Scholar
• De Geyter C, De Geyter M, Castro E, Bals-Pratsch M, Nieschlag E, Schneider H P. Experience with transvaginal ultrasound-guided aspiration of supernumerary follicles for the prevention of multiple pregnancies after ovulation induction and intrauterine insemination. Fertil Steril 1996; 65: 1163–1168
   PubMedGoogle Scholar
• Ferraretti A P, Gianaroli L, Magli M C, Iammarrone E, Feliciani E, Fortini D. Transvaginal ovarian drilling: a new surgical treatment for improving the clinical outcome of assisted reproductive technologies in patients with polycystic ovary syndrome. Fertil Steril 2001; 76: 812–816
   PubMed Web of Science ®Google Scholar
• Kiddy D S, Hamilton-Fairley D, Seppala M, Koistinen R, James V H, Reed M J, Franks S. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989; 31: 757–763
   PubMed Web of Science ®Google Scholar
• Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173–179
   PubMed Web of Science ®Google Scholar
• Clark A M, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman R J. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705–2712
   PubMed Web of Science ®Google Scholar
• Clark A M, Thornley B, Tomlinson L, Galletley C, Norman R J. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13: 1502–1505
   PubMed Web of Science ®Google Scholar
• Norman R J, Davies M J, Lord J, Moran L J. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13: 251–257
   PubMed Web of Science ®Google Scholar
• Huber-Buchholz M M, Carey D G, Norman R J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470–1474
   PubMed Web of Science ®Google Scholar
• Vandermolen D T, Ratts V S, Evans W S, Stovall D W, Kauma S W, Nestler J E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310–315
   PubMed Web of Science ®Google Scholar
• Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002; 77: 101–106
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildiz B O, Demirol A, Zeyneloglu H B, Yigit N, Bukulmez O, Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002; 17: 289–294
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Orio F, Jr, Manguso F, Russo T, Tolino A, Annamaria C, Dale B, Zullo F. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005; 20: 2879–2886
   PubMed Web of Science ®Google Scholar
• George S S, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri M S. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003; 18: 299–304
   PubMed Web of Science ®Google Scholar
• Sturrock N D, Lannon B, Fay T N. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002; 535: 469–473
   Google Scholar
• O'Dea J PK, Wieland R G, Hallberg M C, Llerena L A, Zorm E M, Genuth S M. Effect of dietary weight loss on sex steroid binding, sex steroids, and gonadotrophins in obese premenopausal women. J Lab Clin Med 1979; 93: 1004–1008
   PubMedGoogle Scholar
• Malkawi H Y, Qublan H S, Hamaideh A H. Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol 2003; 23: 289–293
   PubMedGoogle Scholar
• Kashyap S, Wells G A, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004; 19: 2474–2483
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Jakubowicz D J, Iuorno M J, Jakubowicz S, Nestler J E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893–902
   PubMed Web of Science ®Google Scholar
• Balen A H, Tan S L, MacDougall J, Jacobs H S. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8: 959–964
   PubMed Web of Science ®Google Scholar
• Homburg R, Armar N A, Eshel A, Adams J, Jacobs H S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Br Med J 1998; 297: 1024–1026
   Google Scholar
• Regan L, Owen E J, Jacob H S. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 1990; 336: 1141–1144
   PubMed Web of Science ®Google Scholar
• Sagle M, Bishop K, Ridley N, Alexander F M, Michel M, Bonney R C, Beard R W, Franks S. Recurrent early miscarriage and polycystic ovaries. Br Med J 1988; 297: 1027–1028
   PubMed Web of Science ®Google Scholar
• Watson H, Kiddy D S, Hamilton-Fairley D, Scanlon M J, Barnard C, Collins W P, Bonney R C, Franks S. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod 1993; 8: 829–833
   PubMedGoogle Scholar
• Gray R H, Wu L Y. Subfertility and risk of spontaneous abortion. Am J Public Health 2000; 90: 1452–1454
   PubMed Web of Science ®Google Scholar
• Regan L, Braude P R, Trembath P L. Influence of past reproductive performance on risk of spontaneous abortion. Br Med J 1989; 299: 541–545
   PubMed Web of Science ®Google Scholar
• Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 1994; 9: 1328–1332
   PubMed Web of Science ®Google Scholar
• Craig L B, Ke R W, Kutteh W H. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002; 78: 487–490
   PubMed Web of Science ®Google Scholar
• Van der Spuy Z M, Dyer S J. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 755–771
   PubMed Web of Science ®Google Scholar
• Homburg R. Clomiphene citrate – end of an era? A mini-review. Hum Reprod 2005; 20: 2043–2051
   PubMed Web of Science ®Google Scholar
• Jain J K, Kuo J. Pregnancy outcomes with increased clomiphene citrate dose. Gynecol Endocrinol 2004; 19: 141–145
   PubMed Web of Science ®Google Scholar
• Kelekci S, Saygili-Yilmaz E, Inan I, Eminsoy G. A trial of a new regimen with clomiphene citrate administration to reduce the antiestrogenic effects on reproductive end organs. Eur J Obstet Gynecol Reprod Biol 2004; 116: 54–57
   PubMed Web of Science ®Google Scholar
• Lopez E, Gunby J, Daya S, Parrilla J J, Abad L, Balasch J. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod Biomed Online 2004; 94: 382–390
   Google Scholar
• Palomba S, Orio F, Jr, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4068–4074
   PubMed Web of Science ®Google Scholar
• Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol 2003; 1: 109
   PubMedGoogle Scholar
• Van der Meer M, Hompes P, de Boer J, Schats R, Schoemaker J. Cohort size rather than follicle-stimulating hormone threshold levels determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab 1988; 83: 423–426
   Google Scholar
• Homburg R, Howles C M. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, reflections and refinements. Hum Reprod Update 1999; 5: 493–499
   PubMed Web of Science ®Google Scholar
• Seibel M M, Kamrava M M, McArdle C, Taymor M L. Treatment of polycystic ovarian disease with chronic low-dose follicle stimulating hormone: biochemical changes and ultrasound correlation. Int J Fertil 1984; 29: 39–43
   PubMedGoogle Scholar
• Polson D W, Mason H D, Saldahna M BY, Franks S. Ovulation of a single dominant follicle during treatment with low-dose pulsatile FSH in women with PCOS. Clin Endocrinol (Oxf) 1987; 26: 205–212
   PubMed Web of Science ®Google Scholar
• Homburg R, Levi T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995; 63: 729–733
   PubMed Web of Science ®Google Scholar
• Hedon B, Hugues J N, Emparaire J C, Chabaud J J, Barbereau D, Boujenah A, Howles C M, Truong F. A comparative prospective study of a chronic low-dose versus a conventional ovulation stimulation regimen using recombinant human follicle-stimulating hormone in anovulatory infertile women. Hum Reprod 1998; 13: 2688–2692
   PubMed Web of Science ®Google Scholar
• Tummon I, Gavrilova-Jordan L, Allemand M C, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005; 84: 611–616
   PubMed Web of Science ®Google Scholar
• Homburg R, Eshel A, Kilborn J, Adams J, Jacobs H S. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Hum Reprod 1990; 5: 32–37
   PubMedGoogle Scholar
• Olivennes F, Ayoubi J M, Fanchin R, Rongieres-Bertrand C, Hamamah S, Bouchard P, Frydman R. GnRH antagonist in single-dose applications. Hum Reprod Update 2000; 6: 313–317
   PubMed Web of Science ®Google Scholar
• Olivennes F, Cunha-Filho J S, Fanchin R, Bouchard P, Frydman R. The use of Gn-RH antagonist in ovarian stimulation. Hum Reprod Update 2002; 8: 279–290
   PubMed Web of Science ®Google Scholar
• Reissmann T, Schally A V, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000; 6: 322–331
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch K E, Webster B W, Brown C P, Vernon M W. Concurrent ganirelix and follitropin β therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 603–607
   PubMed Web of Science ®Google Scholar
• Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani P G. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005; 20: 2421–2425
   PubMed Web of Science ®Google Scholar
• Guido M, Belosi C, Selvaggi L, Lattanzi F, Apa R, Fulghesu A M, Lanzone A. The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome. Gynecol Endocrinol 2003; 17: 215–221
   PubMedGoogle Scholar
• Baird D T, Collins J, Egozcue J, Evers L H, Gianaroli L, Leridon H, Sunde A, Templeton A, Van Steirteghem A, et al. ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update 2005; 11: 261–276
   PubMed Web of Science ®Google Scholar
• Leridon H. Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment. Hum Reprod 2004; 19: 1548–1553
   PubMed Web of Science ®Google Scholar
• Lipton A, Demers L, Harvey H, Kambic K, Grossberg H, Brady C, Adlercruetz H, Trunet P F, Santen R J. A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995; 75: 2132–2138, Letrozole (GCS 20264).
   PubMed Web of Science ®Google Scholar
• Iveson T, Smith I, Ahern J, Smithers D, Trunet P, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993; 53: 266–270
   PubMed Web of Science ®Google Scholar
• Mitwally M FM, Casper R F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75: 305–309
   PubMed Web of Science ®Google Scholar
• Al-Omari W R, Sulaiman W R, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene resistant polycystic ovary syndrome. Int J Gynecol Obstet 2004; 85: 289–291
   PubMedGoogle Scholar
• Mitwally M FM, Casper R F. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004; 11: 406–415
   PubMedGoogle Scholar
• Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res 2004; 35: 103–108
   PubMed Web of Science ®Google Scholar
• Goswami S K, Das T, Chattopadhyay R, Sawhney V, Chaudhury K, Chakravarty B N, Kabir S N. A randomised single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004; 19: 2031–2035
   PubMed Web of Science ®Google Scholar
• Al-Fozan H, Al-Khadouri M, Tan S L, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004; 82: 1561–1563
   PubMed Web of Science ®Google Scholar
• Mitwally M FM, Biljan M M, Casper R F. Pregnancy outcome after the use of an oral aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005; 192: 381–386
   PubMed Web of Science ®Google Scholar